Go to Samples
Eli Lilly and Co.Verzenio28 x 50mg oral tablets per box
Indications and Usage
VERZENIO® is a kinase inhibitor.
Available in Tablets: 50 mg, 100 mg, 150 mg, and 200 mg provided as immediate-release oval white, beige, or yellow tablets indicated to be taken with or without food twice daily with a recommended and approved starting dose of 150mg for combination therapy or 200mg for monotherapy.
INDICATIONS AND USAGE
VERZENIO ® is a kinase inhibitor indicated:
- in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence.
- in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.
- in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.
- as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.
Early Breast Cancer
VERZENIO ® (abemaciclib) is indicated:
- in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence [see Clinical Studies ].
Advanced or Metastatic Breast Cancer
VERZENIO (abemaciclib) is indicated:
- in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.
- in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.
- as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.
FAQsAll you need to know to order samples
Due to manufacturer restrictions, there are some limitations on the quantities of samples that can be included in each order. We're working on new functionality to let your practice place larger, batch orders.